Biologics have revolutionized cancer treatment, reversed the course of immune-related conditions, and offered new hope for patients with compromised health conditions. Northway Biotech, an end-to-end biologics CDMO, supports its biopharmaceutical clients with a new, state-of-the-art, process development and cGMP manufacturing facility. Having scientific expertise that accelerates time-to-market and that is invested in technology supporting gene to drug product, Northway Biotech presents a virtual, grand opening experience. Click here to register.
By Louis Garguilo, Chief Editor, Outsourced Pharma
When vaccines have been administered and COVID-19 is at bay, hopefully the vaccine makers and their partners will provide the entire drug development and manufacturing industry with details about the challenges they encountered in their supply chains.
By Sanjay Konagurthu, Ph.D., and Tom Reynolds,Thermo Fisher Scientific
Bypassing conventional trial-and-error methods for solubility challenges and excipient selection can eliminate unnecessary testing, improve the efficacy of formulations, and increase overall speed-to-market.
The speed and quantity at which novel vaccines, therapeutics, and candidates are currently entering into clinical development is unparalleled. Capacity for manufacturing these products is in high demand. Due to this ever-changing landscape, it is more important than ever to partner with a CDMO that is proactive with how they plan, resource, and execute programs.
Biotech investigators can’t possibly know everything required to move their drug candidate from the lab bench to the marketplace. Accepting that reality is the first step toward finding a strategic partner whose broad knowledge base and experience complements your specialized expertise. Whom you partner with, and when, can make all the difference down the road.
ISR surveyed 136 sponsors who outsource drug product manufacturing for small molecule compounds to gain insight into their overall satisfaction, willingness to recommend, and likelihood to use the CMO again.
Greg Sears, Ph.D., global director, process characterization, head of manufacturing science and tech, pharma services, biologics at Thermo Fisher Scientific, discusses process characterization basics.
Join us on January 26, 2021, at 10:00 a.m. EST when Cell & Gene’s chief editor, Erin Harris, talks to Acepodia’s Mark Gilbert, M.D., Celyad Oncology’s Thomas Lequertier, and SOTIO’s Luděk Sojka, Ph.D., about the innovations in manufacturing that can reduce both costs and risks in producing new cell and gene therapies.
Are there lessons learned and best practices from the COVID-19 vaccine efforts you can apply to tech transfers of your own projects — be they small molecule, biologics, or cell and gene therapies? View the on-demand version of OP-Virtual from our discussion on November 4, 2020, on what we’ve learned thus far and how to transfer that knowledge to your projects.